Addyi Geriatric (65+) Dosing: What Clinicians and Patients Need to Know

What the FDA Label Actually Says About Geriatric Dosing

The official Addyi prescribing information does not establish a separate geriatric dose. It states that clinical trials enrolled too few women aged 65 and older to draw conclusions about differential safety or efficacy in this population. No pharmacokinetic bridging study in older women has been published to date.

The Label Wording Verbatim

The Addyi prescribing label reads: "Clinical studies of flibanserin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects." This language places Addyi in a large category of drugs approved without strong geriatric trial data, a pattern the FDA has acknowledged as a systemic gap in drug development. The full prescribing information is available at accessdata.fda.gov.

What "No Adjustment Specified" Really Means in Practice

The absence of a specified geriatric dose does not mean the drug is safe by default in older women. It means the evidence gap exists. Clinicians applying geriatric prescribing frameworks, such as the American Geriatrics Society Beers Criteria, must weigh individual patient factors that become substantially more complex after age 65. The 2023 Beers Criteria published in the Journal of the American Geriatrics Society does not list flibanserin by name, but the CNS depressant class warnings and the sedative/hypnotic cautions apply to pharmacologically similar agents.

Approved Dosing Schedule

The single approved regimen is 100 mg by mouth once nightly at bedtime. Daytime dosing is not acceptable because sedation risk is unacceptably high when patients are upright and mobile. The FDA requires this specific timing on the label and enforces it through the Risk Evaluation and Mitigation Strategy (REMS) program. Full REMS details appear on the FDA REMS database.

Pharmacokinetics in Older Adults: Why Age Changes the Math

Flibanserin is metabolized primarily by CYP3A4 and secondarily by CYP2C19. Both pathways are affected by normal aging. Understanding the pharmacokinetic shifts is necessary before interpreting any dosing decision in a 65-plus patient.

Hepatic Metabolism and Age-Related Decline

Hepatic blood flow decreases by approximately 40% between age 25 and age 65, and CYP enzyme activity falls in parallel. A dedicated hepatic impairment study showed that mild hepatic impairment (Child-Pugh A) increased flibanserin exposure (AUC) by approximately 4.5-fold compared with healthy controls, leading to a contraindication for any degree of hepatic impairment on the current label. Older patients are disproportionately likely to have subclinical hepatic changes, even without a formal diagnosis. The FDA pharmacology review supporting this contraindication is referenced in the full NDA review package.

Renal Function and Creatinine Clearance

The Addyi label states no dose adjustment is needed for mild-to-moderate renal impairment based on available studies. However, older patients with glomerular filtration rates below 30 mL/min/1.73m2 were excluded from clinical trials. The National Kidney Foundation notes that eGFR declines at roughly 1 mL/min/year after age 40 in healthy adults, meaning a 70-year-old woman with a "normal" serum creatinine may have an eGFR well below 60. Clinicians should calculate eGFR rather than relying on creatinine alone before initiating flibanserin.

CYP2C19 Genetic Variation

Approximately 2 to 3 percent of Caucasian women and 13 to 23 percent of East Asian women are CYP2C19 poor metabolizers. In this subgroup, flibanserin exposure rises substantially because a secondary clearance route is lost. Age-related changes in CYP3A4 compound the effect. A PubMed-indexed pharmacogenomics review documents the interaction between CYP2C19 phenotype and flibanserin disposition and concludes that poor metabolizers may experience higher sedation burden at standard doses. Routine CYP2C19 genotyping is not required by the label, but clinicians managing older patients on concurrent CYP2C19 substrates should factor in this possibility.

Fall and Fracture Risk in Women Over 65

Falls are the leading cause of injury-related death in adults aged 65 and older. The CDC reports that approximately 36 million falls occur annually among older adults in the United States, resulting in more than 32,000 deaths each year. Flibanserin produces dose-dependent CNS depression. Combining that CNS depression with the physiology of an older adult is not a trivial clinical decision.

The Sedation Mechanism

Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with additional antagonist effects at dopamine D4 receptors. These mechanisms produce sedation. In placebo-controlled trials, somnolence occurred in 11% of patients on flibanserin 100 mg versus 4% on placebo, and fatigue occurred in 11% versus 6%, according to data summarized in the FDA drug approval summary. Older adults already have reduced postural stability, slower reflex arcs, and thinner cortical bone. Adding a CNS depressant at bedtime raises the risk of nocturnal or early-morning falls when patients get up to use the bathroom.

Orthostatic Hypotension

Flibanserin lowers blood pressure through its adrenergic properties. Orthostatic hypotension, defined as a systolic drop of 20 mmHg or more on standing, affects an estimated 20 to 30 percent of community-dwelling adults over age 65, based on data reviewed in this JAMA Internal Medicine analysis. Adding flibanserin to a patient who already experiences postural dizziness is a compounding risk. The alcohol contraindication is partly rooted in the same mechanism: alcohol plus flibanserin caused clinically meaningful drops in blood pressure in the dedicated pharmacodynamic study that led the FDA to require alcohol abstinence as a condition of the REMS.

Beers Criteria and CNS-Active Drugs

The American Geriatrics Society Beers Criteria 2023 update strongly recommends avoiding CNS-active medications in older adults unless alternative options have been exhausted. The criteria published in JAGS specifically flag sedative-hypnotics, serotonergic agents, and drugs that lower blood pressure as contributors to falls and cognitive impairment. Flibanserin shares properties with all three categories.

Drug-Drug Interactions That Become More Dangerous With Age

Polypharmacy is the norm, not the exception, in adults over 65. The average Medicare beneficiary fills prescriptions from 4 or more prescribers and takes 5 or more chronic medications. Several drug classes that appear routinely in older patients' medication lists interact dangerously with flibanserin.

CYP3A4 Inhibitors: A Hard Contraindication

Strong and moderate CYP3A4 inhibitors are contraindicated with flibanserin. The label lists fluconazole, ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, and several others. In the drug interaction study using fluconazole 200 mg daily for 4 days, flibanserin AUC increased 7-fold and Cmax increased 2-fold, producing severe hypotension and syncope in study participants. The PubMed-indexed pharmacology paper documenting these interactions concludes that the risk with strong CYP3A4 inhibitors is not manageable through dose reduction. Older women being treated for recurrent vulvovaginal candidiasis with fluconazole, a common scenario, cannot safely take flibanserin concurrently.

CNS Depressants and Polypharmacy

Benzodiazepines, sleep aids, antihistamines, opioids, muscle relaxants, and certain antihypertensives all compound the sedation and hypotension associated with flibanserin. A NIH-indexed review of polypharmacy in older adults found that the median number of potential drug-drug interactions per patient increases from 1 in those taking 5 medications to 6 or more in those taking 10 or more medications. Many women aged 65 and older fall into the 10-plus medication category.

SSRIs and Serotonergic Load

Flibanserin is not an SSRI, but it has serotonergic activity. Concurrent use with SSRIs or SNRIs, prescribed widely for depression and anxiety in older adults, was not systematically studied in the key trials. The FDA pharmacology review flags serotonin syndrome as a theoretical concern in combination with other serotonergic drugs. The interaction does not carry a contraindication on the label, but the signal warrants monitoring in any patient on dual serotonergic therapy.

Digoxin Interaction

Flibanserin increased digoxin AUC by 23% and Cmax by 22% in a pharmacokinetic interaction study. Digoxin has a narrow therapeutic index and is still used in older patients for rate control in atrial fibrillation. This pharmacokinetic interaction is documented in the Addyi prescribing label and should prompt digoxin level monitoring if flibanserin is initiated in a patient already stabilized on digoxin.

What Trial Evidence Exists for Flibanserin in This Age Group

The BEGONIA trial (J Sex Med 2014, N=949) is one of three key trials that supported FDA approval. BEGONIA randomized premenopausal women to flibanserin 100 mg at bedtime or placebo for 24 weeks and found a statistically significant increase in satisfying sexual events (SSEs) per month, with flibanserin producing a mean increase of approximately 0.5 additional SSEs per month over placebo. The full trial is indexed at PubMed PMID 24628797.

The Age Enrollment Gap

The BEGONIA trial, like the other two key studies (SNOWDROP and VIOLET), enrolled predominantly women between ages 22 and 54. The mean age in BEGONIA was approximately 36 years. Women 65 and older represented a negligible fraction of the combined trial population of roughly 2,400 participants. This is not a minor footnote. It means that every efficacy and safety number cited in the prescribing information is derived almost entirely from women whose physiology, comorbidity burden, and medication list are systematically different from a 70-year-old patient.

Postmenopausal Status and HSDD

The FDA approved flibanserin specifically for premenopausal women. The agency's concern about postmenopausal use relates to both the trial gap and the different hormonal milieu driving HSDD in that population. A 65-year-old woman is, by definition, postmenopausal and falls outside the labeled indication. Prescribing flibanserin to her constitutes off-label use. The Endocrine Society Clinical Practice Guideline on female sexual dysfunction notes that HSDD in postmenopausal women may respond differently to serotonergic agents than HSDD in premenopausal women because estrogen withdrawal itself changes central serotonin receptor density and affinity.

The Modest Efficacy Signal in Context

Even in the population where flibanserin was studied, the benefit was modest. A Cochrane-indexed systematic review of flibanserin summarized the pooled trial data and found a mean difference of 0.49 additional SSEs per month versus placebo and an improvement of approximately 0.3 points on a desire-domain score, while adverse event rates were meaningfully higher in the active drug group. Somnolence, dizziness, and nausea were the most common reasons for discontinuation. In an older patient population with reduced physiologic reserve, these adverse events carry greater clinical weight.

The REMS Program and What It Requires

Flibanserin is the only oral agent for HSDD subject to a REMS program. The REMS, maintained by Sprout Pharmaceuticals and overseen by the FDA, requires prescriber certification, pharmacy certification, and patient enrollment.

Prescriber Obligations

Certified prescribers must counsel patients to avoid alcohol completely during treatment, not to take flibanserin with moderate or strong CYP3A4 inhibitors, and not to take it with hepatic impairment. They must also verify that patients understand the syncope and sedation risks and agree not to drive within 6 hours of taking a dose. The FDA REMS program page lists the current certification requirements for both prescribers and dispensing pharmacies.

Patient Enrollment and Counseling

Patients must acknowledge receipt of a medication guide before their first prescription is filled. The guide details the alcohol prohibition and explains that syncope has been reported in the clinical trials and post-marketing period. For older patients, the practical question is whether alcohol abstinence is reliably achievable. Moderate alcohol use, defined as up to one drink per day, is common in women over 65 and is not always disclosed to prescribers.

Clinical Decision Framework for Prescribers Considering Flibanserin in a 65+ Patient

The following stepwise framework reflects the convergence of FDA label language, Beers Criteria guidance, and basic geriatric pharmacology principles. It is intended to structure the prescribing conversation, not replace clinical judgment.

Step 1. Confirm the indication applies. Flibanserin is approved for premenopausal women. Use in a postmenopausal woman aged 65 or older is off-label. Document this status and the clinical rationale explicitly in the chart.

Step 2. Obtain a complete medication list. Cross-reference every current drug against the CYP3A4 inhibitor contraindication list and the CNS depressant additive risk list. A NIH-indexed drug interaction database can support this step. Any strong CYP3A4 inhibitor is a hard stop.

Step 3. Calculate eGFR and review liver function. Any degree of hepatic impairment is a contraindication per the label. Renal impairment below 30 mL/min/1.73m2 was excluded from trials and warrants caution. Use the NIH NIDDK eGFR calculator guidance to confirm current renal function.

Step 4. Assess fall risk formally. Tools such as the Timed Up and Go test and the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm from the CDC STEADI initiative provide structured fall-risk scores. A patient with a high fall risk score should not receive a CNS-active, blood-pressure-lowering sedative at bedtime without an explicit safety plan.

Step 5. Confirm alcohol abstinence is achievable. Use a validated screening tool such as the AUDIT-C. Patients who cannot reliably abstain should not receive flibanserin. The alcohol-flibanserin interaction produced mean systolic blood pressure drops of more than 20 mmHg in a controlled pharmacodynamic study, a drop large enough to cause syncope and fall in an upright patient.

Step 6. Re-evaluate at 8 weeks. The FDA label states flibanserin should be discontinued if no improvement in satisfying sexual events is apparent by 8 weeks. This timeline applies equally to older patients and prevents prolonged exposure to a drug with meaningful adverse effect risk in this population.

Monitoring Parameters After Initiation

If a clinician proceeds with prescribing after completing the framework above, the following monitoring approach is appropriate.

Blood Pressure and Orthostatic Checks

Measure lying and standing blood pressure at the first follow-up visit after initiation, ideally at 2 to 4 weeks. An orthostatic drop of 20 mmHg systolic or 10 mmHg diastolic meets the clinical definition of orthostatic hypotension, based on criteria from the American Heart Association. If present, discontinue or reduce antihypertensive co-medications before continuing flibanserin.

Cognitive Monitoring

The Montreal Cognitive Assessment (MoCA) or Mini-Cog can document baseline cognitive function before starting any CNS-active drug in a patient over 65. A PubMed-indexed geriatric pharmacology review recommends formal cognitive baseline assessments before initiating sedating agents in adults over 70, particularly those already using one or more CNS-active drugs.

Sedation and Functional Assessment

Ask directly about morning-after sedation, dizziness on rising, and any near-falls at each follow-up. The patient's report is the primary monitoring tool because no biomarker for sedation burden exists. Discontinue if the patient reports functional limitation from sedation, even if it occurs only after the first dose.

Deprescribing Considerations

Geriatric medicine increasingly emphasizes deprescribing as an active clinical intervention, not merely a default. Flibanserin is not habit-forming in the classical sense, and abrupt discontinuation does not produce a documented withdrawal syndrome. This makes it easier to stop than many other CNS-active drugs in older patients' medication lists.

The Canadian Deprescribing Network framework recommends reviewing all CNS-active drugs annually in patients over 65 and asking whether the original indication still applies. For flibanserin, the original labeled indication (premenopausal HSDD) becomes less applicable with each year of postmenopausal aging, and the risk-benefit ratio may shift further against continuation as comorbidity burden accumulates.

Summary of Key Numbers Clinicians Should Cite

The table below consolidates the specific figures that drive prescribing decisions in this age group.

| Parameter | Value | Source | |---|---|---| | Approved dose | 100 mg nightly at bedtime | FDA label | | Hepatic impairment AUC increase | ~4.5-fold (Child-Pugh A) | FDA pharmacology review | | Digoxin AUC increase | 23% | FDA label | | Fluconazole interaction AUC increase | ~7-fold | Published DDI study | | SSE improvement vs placebo (BEGONIA) | ~0.5 events/month | PMID 24628797 | | Somnolence rate (flibanserin vs placebo) | 11% vs 4% | FDA label | | Annual US falls in adults 65+ | ~36 million | CDC | | 8-week discontinuation rule | Stop if no benefit | FDA label |